Plain-English translation of NCT06953622 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →This trial is building a long-term registry of migraine patients who also have patent foramen ovale—a small opening in the heart that many people are born with. Researchers will follow patients who choose three different paths: taking antiplatelet medication (blood thinners), having surgery to close the opening, or managing with conservative care alone. The goal is to understand which approach works best for reducing migraine symptoms and improving quality of life.
Many people with migraines also have patent foramen ovale, but doctors aren't sure which treatment is most effective. This study aims to fill that gap by following real patients over time and learning which options lead to the best outcomes.
You likely qualify if…
You likely don't qualify if…
You will join one of three groups based on your choice and your doctor's recommendation: conservative management (no surgery or blood thinners), antiplatelet medication, or heart surgery to close the opening. Throughout the study, you'll have clinical visits, imaging tests, and lab work to track your migraine patterns and overall health. Researchers will collect information about your symptoms, quality of life, and how well each approach is working for you over time.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China
Sponsor
Peking University Third Hospital
Enrollment target
~330 participants
Started
January 2024
Primary completion
December 2026
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yu Fu
Peking University Third Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.